What is Videregen?
Videregen operates at the vanguard of biotechnology, specializing in tissue repair through the application of thymus stem cell science. The company's core innovation, the BioThymus platform, is engineered to rejuvenate thymus function, which is essential for robust T cell development. By targeting the underlying mechanisms of immune deterioration, Videregen addresses a critical gap in current medical treatments for age-related pathologies and transplant tolerance. Their market position is defined by a commitment to high-impact immunology, serving healthcare sectors that require sophisticated regenerative interventions to halt or reverse chronic immune dysfunction.
How much funding has Videregen raised?
Videregen has raised a total of $6.4M across 3 funding rounds:
Multiple Rounds
$6.4M
Private Equity (2014): $2M with participation from North West Fund
Grant (2014): $4M led by North West Fund for Biomedical
Angel/Seed (2014): $481K supported by London Business Angel
Key Investors in Videregen
North West Fund
The North West Fund is a 155 million pound investment fund aimed at providing debt and equity funding to small and medium-sized enterprises in the North West of England. It was established to fill a gap in the lending, venture capital, and private equity markets.
London Business Angel
A prominent network of angel investors providing early-stage capital and strategic mentorship to high-growth startups across various sectors.
What's next for Videregen?
With the recent influx of capital, Videregen is well-positioned to accelerate its clinical development pipeline and refine its BioThymus technology. The strategic focus will likely shift toward scaling manufacturing processes and initiating rigorous clinical trials to validate the efficacy of their regenerative therapies. As the company moves deeper into the enterprise-level funding stage, the emphasis will remain on establishing long-term partnerships within the global immunology market. Future growth will be contingent upon the successful translation of their stem cell research into scalable, regulatory-approved medical solutions that address the growing demand for age-related immune support.
See full Videregen company page
